Antiangiogenic Gene Therapy With Soluble VEGFR-1, -2, and -3 Reduces the Growth of Solid Human Ovarian Carcinoma in Mice

This publication has 38 references indexed in Scilit:

• A highly reproducible xenograft model for human ovarian carcinoma and application of MRI and ultrasound in longitudinal follow-up
  Gynecologic Oncology, 2006
• Differential Roles of Vascular Endothelial Growth Factor Receptor-1 and Receptor-2 in Angiogenesis
  BMB Reports, 2006
• Soluble FLT-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer.
  2002
• A model for gene therapy of human hereditary lymphedema
  Proceedings of the National Academy of Sciences, 2001
• Evaluation of Recombinant Human Interleukin-12 in Patients with Recurrent or Refractory Ovarian Cancer: A Gynecologic Oncology Group Study
  Gynecologic Oncology, 2001
• Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice
  The EMBO Journal, 2001
• Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3
  Nature Medicine, 2001
• Magnetic Resonance Imaging to Measure Therapeutic Response Using an Orthotopic Model of Human Pancreatic Cancer
  Pancreas, 2000
• Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ.
  2000
• Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer
  British Journal of Cancer, 2000